Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) Director Wayne Joseph Riley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $98.03, for a total transaction of $1,470,450.00. Following the sale, the director now directly owns 200 shares in the company, valued at approximately $19,606. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

VRTX has been the subject of a number of recent research reports. Analysts at Goldman Sachs raised their price target on shares of Vertex Pharmaceuticals to $109.00 in a research note on Wednesday. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday. They now have a $136.00 price target on the stock, up previously from $103.00. Finally, analysts at Sanford C. Bernstein raised their price target on shares of Vertex Pharmaceuticals from $65.00 to $107.00 in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. Vertex Pharmaceuticals has an average rating of “Hold” and a consensus target price of $100.41.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 3.68% on Thursday, hitting $93.17. 5,511,777 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a one year low of $58.06 and a one year high of $98.80. The stock’s 50-day moving average is $70.60 and its 200-day moving average is $73.5. The company’s market cap is $22.006 billion. Vertex Pharmaceuticals also was the recipient of unusually large options trading activity on Monday. Investors bought 13,082 call options on the stock. This represents an increase of 235% compared to the average volume of 3,903 call options.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, May 1st. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. The company’s quarterly revenue was down 63.9% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.89 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.